# Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

> **NCT02465450** · PHASE2 · COMPLETED · sponsor: **Corbus Pharmaceuticals Inc.** · enrollment: 85 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** JBT-101 (lenabasum)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02465450
- **Lead sponsor:** Corbus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-29
- **Primary completion:** 2016-12-28
- **Final completion:** 2016-12-28
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2018-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465450, "Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02465450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*